Next Article in Journal
Molecular Mechanisms Underlying NMDARs Dysfunction and Their Role in ADHD Pathogenesis
Next Article in Special Issue
Blood-Based Transcriptomic Biomarkers Are Predictive of Neurodegeneration Rather Than Alzheimer’s Disease
Previous Article in Journal
Discovery of α-Linolenic Acid 16(S)-Lipoxygenase: Cucumber (Cucumis sativus L.) Vegetative Lipoxygenase 3
Previous Article in Special Issue
The UPR Maintains Proteostasis and the Viability and Function of Hippocampal Neurons in Adult Mice
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 24
Issue 16
10.3390/ijms241612982
Review Report
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

Potential Role of Antibodies against Aquaporin-1 in Patients with Central Nervous System Demyelination

Int. J. Mol. Sci. 2023, 24(16), 12982; https://doi.org/10.3390/ijms241612982
by Maria Pechlivanidou 1,†, Konstantina Xenou 1,†, Dimitrios Tzanetakos 2, Emmanuel Koutsos 1, Christos Stergiou 1, Elisabeth Andreadou 3, Konstantinos Voumvourakis 2, Sotirios Giannopoulos 2, Constantinos Kilidireas 3,4, Erdem Tüzün 5, Georgios Tsivgoulis 2, Socrates Tzartos 1,6,7 and John Tzartos 2,*
Reviewer 1:
Yuji Tomizawa
Int. J. Mol. Sci. 2023, 24(16), 12982; https://doi.org/10.3390/ijms241612982
Submission received: 28 June 2023 / Revised: 9 August 2023 / Accepted: 17 August 2023 / Published: 19 August 2023
(This article belongs to the Special Issue Molecular Aspects of the Neurodegenerative Brain Diseases)

Round 1

Reviewer 1 Report

The authors explained the outline of aquaporin and described in detail multiple measurement methods for AQP1.

Evidence that anti-AQP1 antibodies can cause cell damage in some way is not sufficient to deny the authors’ claim, so there is some likelihood to their argument.

On the other hand, considering the distribution of AQP1, it seems unlikely that AQP1 autoimmunity is a necessity for NMO phenotype.

Further accumulation of disease transfer models and other evidence is necessary to discuss the pathogenicity of anti-AQP1 antibodies.

Author Response

Please see the attachment 

Author Response File: Author Response.docx

Reviewer 2 Report

1-      NMOSD is recognized as an astrocytopathy and it differs from demyelinating disorders substantially. So, it should be corrected in abstract and manuscript.

2-      Why have the authors chosen  AQ1 for this study? They should explain why this type of AQs is important.

3-      I think the focus of this review should be on the role of AQ1. The authors should discuss AQ4 in the introduction and omit it from section 2.

4-      They should discuss the role of AQ1 in the health in separate section. After that, they should explain its role in autoimmune diseases in another section.

5-      The most of manuscript has been specified to different methods of AQ1 assays which isn’t related to the main purpose of this study. The authors should review the role of AQ1 in the different diseases and they should just mention the assays in a separate section in brief.

6-      The manuscript should be re-written and can not be accepted in this form.

Author Response

Please see the attachment 

Author Response File: Author Response.docx

Round 2

Reviewer 2 Report

unfortunately the authors' response has not been attached to the revised manuscript. They should answer the comments word by word. It seems that most of my comments have not been considered in their revision.

Author Response

Please see the attachment 

Author Response File: Author Response.pdf

Round 3

Reviewer 2 Report

This manuscript is ready to publish.

Back to TopTop